Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RYTM

RYTM - Rhythm Pharmaceuticals Inc Stock Price, Fair Value and News

42.75USD-1.62 (-3.65%)Market Closed

Market Summary

RYTM
USD42.75-1.62
Market Closed
-3.65%

RYTM Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

RYTM Stock Price

View Fullscreen

RYTM RSI Chart

RYTM Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-9.52

Price/Sales (Trailing)

28.36

EV/EBITDA

-9.71

Price/Free Cashflow

-18.55

RYTM Price/Sales (Trailing)

RYTM Profitability

EBT Margin

-302.94%

Return on Equity

-444.73%

Return on Assets

-105.88%

Free Cashflow Yield

-5.39%

RYTM Fundamentals

RYTM Revenue

Revenue (TTM)

91.9M

Rev. Growth (Yr)

126.41%

Rev. Growth (Qtr)

7.15%

RYTM Earnings

Earnings (TTM)

-273.9M

Earnings Growth (Yr)

-170.94%

Earnings Growth (Qtr)

-239.57%

Breaking Down RYTM Revenue

Last 7 days

7.0%

Last 30 days

8.0%

Last 90 days

6.9%

Trailing 12 Months

133.9%

How does RYTM drawdown profile look like?

RYTM Financial Health

Current Ratio

4.35

Debt/Equity

1.18

Debt/Cashflow

-1.93

RYTM Investor Care

Shares Dilution (1Y)

7.24%

Diluted EPS (TTM)

-3.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202491.9M000
202333.6M43.8M62.0M77.4M
20228.3M13.4M18.5M23.6M
20210003.2M

Tracking the Latest Insider Buys and Sells of Rhythm Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 09, 2024
shulman joseph
acquired
54,182
6.8
7,968
chief technical officer
May 09, 2024
shulman joseph
sold
-306,517
38.4685
-7,968
chief technical officer
Apr 14, 2024
mazabraud yann
sold
-
-
-10,375
evp, head of international
Apr 02, 2024
german christopher paul
sold
-15,367
41.76
-368
corporate controller & cao
Mar 21, 2024
shulman joseph
sold
-735,600
40.34
-18,235
chief technical officer
Mar 20, 2024
german christopher paul
acquired
-
-
1,163
corporate controller & cao
Mar 20, 2024
lee jennifer kayden
sold
-707,005
38.7719
-18,235
evp, head of north america
Mar 19, 2024
lee jennifer kayden
sold
-608,498
39.22
-15,515
evp, head of north america

1–10 of 50

Which funds bought or sold RYTM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 29, 2024
Opaleye Management Inc.
reduced
-15.57
-5,726,750
22,315,000
4.86%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
69.09
186,938
500,938
0.06%
May 20, 2024
Virtu Financial LLC
sold off
-100
-1,218,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-85.72
-7,334,620
1,140,360
-%
May 16, 2024
COMERICA BANK
reduced
-2.74
-130,299
1,435,000
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.25
-177,145
2,075,250
-%
May 16, 2024
CASTLEARK MANAGEMENT LLC
new
-
2,768,790
2,768,790
0.12%
May 15, 2024
Rock Springs Capital Management LP
unchanged
-
-4,020,440
65,987,000
1.68%
May 15, 2024
Parkwood LLC
added
47.41
182,000
651,000
0.06%
May 15, 2024
VR Adviser, LLC
sold off
-100
-22,800,300
-
-%

1–10 of 42

Are Funds Buying or Selling RYTM?

Are funds buying RYTM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RYTM
No. of Funds

Unveiling Rhythm Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 30, 2024
new enterprise associates 13 lp
-
0
SC 13D/A
Apr 17, 2024
perceptive advisors llc
8.3%
5,143,575
SC 13D/A
Apr 03, 2024
perceptive advisors llc
5.4%
3,268,579
SC 13D/A
Mar 20, 2024
perceptive advisors llc
5.4%
3,268,579
SC 13D
Feb 14, 2024
ra capital management, l.p.
9.0%
5,330,412
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
10.8%
6,398,365
SC 13G/A
Feb 13, 2024
vanguard group inc
5.46%
3,226,938
SC 13G
Feb 12, 2024
primecap management co/ca/
13.63%
8,052,648
SC 13G/A
Feb 12, 2024
perceptive advisors llc
5.5%
3,260,013
SC 13G
Feb 05, 2024
goldman sachs group inc
8.5%
4,998,761
SC 13G/A

Recent SEC filings of Rhythm Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
May 13, 2024
4
Insider Trading
May 09, 2024
144
Notice of Insider Sale Intent
May 07, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report
Apr 30, 2024
SC 13D/A
13D - Major Acquisition
Apr 26, 2024
ARS
ARS
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A
Apr 17, 2024
SC 13D/A
13D - Major Acquisition
Apr 16, 2024
4
Insider Trading

Peers (Alternatives to Rhythm Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Rhythm Pharmaceuticals Inc News

Latest updates
Defense World9 hours ago
MarketBeat13 Jun 202409:22 pm

Rhythm Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue7.2%25,967,00024,234,00022,504,00019,221,00011,469,0008,790,0004,284,0009,066,0001,498,000----
Costs and Expenses153.2%165,854,00065,501,00066,457,00065,825,00064,000,00050,893,00043,551,00054,162,00054,189,00052,806,00045,268,00040,706,00034,433,000
  S&GA Expenses6.2%34,382,00032,375,50030,475,00030,046,00024,634,00026,317,00021,938,00022,328,00021,449,00020,996,00017,507,00015,465,00014,518,000
  R&D Expenses330.4%128,665,00029,892,50033,570,00033,543,00037,945,00023,548,00021,116,00031,456,00032,510,00031,574,00027,539,00025,104,00019,911,000
EBITDA Margin-33.4%-2.86-2.14-2.79-4.00-5.20-7.40-------
Interest Expenses6.5%4,755,0004,464,5003,149,0003,303,0003,061,000-2,144,00046,000-----
Income Taxes53.1%300,000196,000368,000--------8,995,000-5,022,00022,006,000
Earnings Before Taxes-240.4%-141,072,000-41,437,000-43,795,000--52,179,000-42,493,000-40,861,000---63,840,000--40,411,00065,756,000
EBT Margin-30.4%-3.03-2.32-2.89-4.14-5.39-7.66-3.76-5.20-8.41-22.07---
Net Income-239.6%-141,372,000-41,633,000-44,163,000-46,703,000-52,179,000-42,493,000-40,861,000-45,001,000-52,764,000-42,866,000-35,107,000-35,389,00043,750,000
Net Income Margin-24.9%-2.98-2.39-2.99-4.16-5.37-7.66-9.80-13.12-20.08-22.07---
Free Cashflow-38.7%-40,742,000-29,382,000-29,252,000-41,090,000-36,480,000-33,999,000-47,082,000-38,869,000-53,759,000-40,540,000-40,266,000-32,088,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-22.3%259333354310346382390278285330356388422187215243274309178211237
  Current Assets-23.5%236308329284318354362249253308336378412182210238268302171204230
    Cash Equivalents-11.1%53.0060.0065.0011611012818511379.0059.0092.0069.0087.0010168.0059.0056.0063.0072.0064.0042.00
  Inventory-1.4%9.009.008.006.005.003.00---0.00-----------
  Net PPE-14.3%1.001.002.002.002.002.002.003.003.003.003.003.003.003.003.003.004.004.004.004.003.00
Liabilities20.9%19716315712812611810882.0049.0045.0034.0037.0041.0021.0019.0018.0021.0028.0028.0029.0016.00
  Current Liabilities-1.9%54.0055.0050.0046.0046.0040.0033.0045.0047.0043.0023.0017.0017.0018.0016.0015.0018.0024.0025.0026.0013.00
  Long Term Debt-------73.0034.00-------------
Shareholder's Equity-63.7%62.00170197182220264281196236284322352381167197226253281149181220
  Retained Earnings-15.8%-1,036-894-853-808-762-710-667-626-581-528-486-450-415-459-424-390-359-325-292-256-213
  Additional Paid-In Capital3.1%1,0981,0641,051991982974949823818813808803797626621616613606441438434
Shares Outstanding2.6%61.0059.0059.0057.0057.0057.0051.0050.0050.0050.0050.0050.00---------
Float----887---188---884---828---569-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-38.7%-40,743-29,383-29,251-41,090-36,433-34,000-46,987-38,809-53,632-40,472-40,160-31,840-33,531-29,122-27,031-29,729-36,098-32,221-33,605-25,546-31,378
  Share Based Compensation-10.5%7,7678,6748,6128,8916,3765,2874,7965,1374,6114,6765,2685,6695,1914,2574,6953,0285,4752,9243,0353,2722,644
Cashflow From Investing32.7%30,05022,640-94,96048,19118,464-40,775-39,69735,97972,5227,24862,78013,525-145,71261,88734,91032,86128,873-139,12741,47146,14523,541
Cashflow From Financing75.1%4,2432,42373,043-965-13317,365158,56437,500399100413383165,585420699183707161,963697498316
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RYTM Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenues$ 25,967$ 11,469
Costs and expenses:  
Cost of sales2,8071,421
Research and development128,66537,945
Selling, general, and administrative34,38224,634
Total costs and expenses165,85464,000
Loss from operations(139,887)(52,531)
Other (expense) income:  
Other income (expense), net524(27)
Interest expense(4,755)(3,061)
Interest income3,0463,440
Total other (expense) income, net(1,185)352
Loss before taxes(141,072)(52,179)
Provision for income taxes300 
Net loss$ (141,372)$ (52,179)
Net loss per share, basic (in dollars per share)$ (2.35)$ (0.92)
Weighted-average common shares outstanding, basic (in shares)60,143,55856,708,975
Other comprehensive loss:  
Net Income (Loss)$ (141,372)$ (52,179)
Foreign currency translation adjustment(71)21
Unrealized gain (loss), net on marketable securities(244)65
Comprehensive loss(141,687)(52,093)
Product revenue  
Total revenues$ 25,967$ 11,469

RYTM Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 53,428$ 60,081
Short-term investments147,771215,765
Accounts receivable, net14,69514,867
Inventory8,5078,624
Prepaid expenses and other current assets11,3528,931
Total current assets235,753308,268
Property and equipment, net1,1491,341
Right-of-use asset670781
Intangible assets, net6,8157,028
Restricted cash460328
Other long-term assets13,80414,999
Total assets258,651332,745
Current liabilities:  
Accounts payable7,5504,885
Accrued expenses and other current liabilities44,53148,262
Deferred revenue1,2861,286
Lease liability793770
Total current liabilities54,16055,203
Long-term liabilities:  
Deferred royalty obligation107,368106,143
Lease liability, non-current284490
Derivative liability6601,150
Other long-term liabilities34,598 
Total liabilities197,070162,986
Stockholders' equity:  
Common stock, $0.001 par value: 120,000,000 shares authorized; 59,426,559 and 56,612,429 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively6059
Additional paid-in capital1,097,8101,064,302
Accumulated other comprehensive income (loss)(181)134
Accumulated deficit(1,036,108)(894,736)
Total stockholders' equity61,581169,759
Total liabilities and stockholders' equity$ 258,651$ 332,745
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEhttps://rhythmtx.com
 INDUSTRYBiotechnology
 EMPLOYEES177

Rhythm Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Rhythm Pharmaceuticals Inc? What does RYTM stand for in stocks?

RYTM is the stock ticker symbol of Rhythm Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rhythm Pharmaceuticals Inc (RYTM)?

As of Fri Jun 14 2024, market cap of Rhythm Pharmaceuticals Inc is 2.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RYTM stock?

You can check RYTM's fair value in chart for subscribers.

What is the fair value of RYTM stock?

You can check RYTM's fair value in chart for subscribers. The fair value of Rhythm Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rhythm Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RYTM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rhythm Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RYTM is over valued or under valued. Whether Rhythm Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rhythm Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RYTM.

What is Rhythm Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, RYTM's PE ratio (Price to Earnings) is -9.52 and Price to Sales (PS) ratio is 28.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RYTM PE ratio will change depending on the future growth rate expectations of investors.